
	Mr. Mortimer has over 15 years experience in the biotechnology sector. He is currently Executive Vice President and Chief Financial Officer at Tekmira Pharmaceuticals Corporation (Tekmira), a Nasdaq-listed biotechnology company focused on advancing RNAi therapeutic products. Mr. Mortimer is responsible for all aspects of Tekmira&#39;s finance and capital markets activities and led Tekmira&#39;s listing on Nasdaq in 2010. Prior to his most recent position at Tekmira, Mr. Mortimer was Chief Financial Officer at Inex Pharmaceuticals Corporation. Mr. Mortimer has an MBA from Queen&#39;s University, a B.Sc. in Microbiology from the University of British Columbia and is a Certified Management Accountant. Mr. Mortimer will join Xenon as Chief Financial Officer full time by November 1, 2013.
